Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes.

Barouch DH, Kunstman J, Kuroda MJ, Schmitz JE, Santra S, Peyerl FW, Krivulka GR, Beaudry K, Lifton MA, Gorgone DA, Montefiori DC, Lewis MG, Wolinsky SM, Letvin NL.

Nature. 2002 Jan 17;415(6869):335-9.

PMID:
11797012
2.

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, Huang L, Harris VA, Long RS, Liang X, Handt L, Schleif WA, Zhu L, Freed DC, Persaud NV, Guan L, Punt KS, Tang A, Chen M, Wilson KA, Collins KB, Heidecker GJ, Fernandez VR, Perry HC, Joyce JG, Grimm KM, Cook JC, Keller PM, Kresock DS, Mach H, Troutman RD, Isopi LA, Williams DM, Xu Z, Bohannon KE, Volkin DB, Montefiori DC, Miura A, Krivulka GR, Lifton MA, Kuroda MJ, Schmitz JE, Letvin NL, Caulfield MJ, Bett AJ, Youil R, Kaslow DC, Emini EA.

Nature. 2002 Jan 17;415(6869):331-5.

PMID:
11797011
3.

Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.

Ortiz GM, Wellons M, Brancato J, Vo HT, Zinn RL, Clarkson DE, Van Loon K, Bonhoeffer S, Miralles GD, Montefiori D, Bartlett JA, Nixon DF.

Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13288-93. Epub 2001 Oct 30.

4.

Vpr is preferentially targeted by CTL during HIV-1 infection.

Altfeld M, Addo MM, Eldridge RL, Yu XG, Thomas S, Khatri A, Strick D, Phillips MN, Cohen GB, Islam SA, Kalams SA, Brander C, Goulder PJ, Rosenberg ES, Walker BD; HIV Study Collaboration.

J Immunol. 2001 Sep 1;167(5):2743-52.

5.

Less is more? STI in acute and chronic HIV-1 infection.

Altfeld M, Walker BD.

Nat Med. 2001 Aug;7(8):881-4. No abstract available.

PMID:
11479610
6.
7.

The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection.

García F, Plana M, Ortiz GM, Bonhoeffer S, Soriano A, Vidal C, Cruceta A, Arnedo M, Gil C, Pantaleo G, Pumarola T, Gallart T, Nixon DF, Miró JM, Gatell JM.

AIDS. 2001 Jun 15;15(9):F29-40.

PMID:
11416735
8.

HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection.

Ruiz L, Carcelain G, Martínez-Picado J, Frost S, Marfil S, Paredes R, Romeu J, Ferrer E, Morales-Lopetegi K, Autran B, Clotet B.

AIDS. 2001 Jun 15;15(9):F19-27.

PMID:
11416734
9.

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, Montefiori DC, Xu Y, Herndon JG, Wyatt LS, Candido MA, Kozyr NL, Earl PL, Smith JM, Ma HL, Grimm BD, Hulsey ML, Miller J, McClure HM, McNicholl JM, Moss B, Robinson HL.

Science. 2001 Apr 6;292(5514):69-74.

10.

Naïve CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation.

van Stipdonk MJ, Lemmens EE, Schoenberger SP.

Nat Immunol. 2001 May;2(5):423-9.

PMID:
11323696
12.

Cellular immune responses to HIV.

McMichael AJ, Rowland-Jones SL.

Nature. 2001 Apr 19;410(6831):980-7. Review.

PMID:
11309628
13.

New insights into host factors in HIV-1 pathogenesis.

Rowland-Jones S, Pinheiro S, Kaul R.

Cell. 2001 Feb 23;104(4):473-6. Review. No abstract available.

14.

Rapid definition of five novel HLA-A*3002-restricted human immunodeficiency virus-specific cytotoxic T-lymphocyte epitopes by elispot and intracellular cytokine staining assays.

Goulder PJ, Addo MM, Altfeld MA, Rosenberg ES, Tang Y, Govender U, Mngqundaniso N, Annamalai K, Vogel TU, Hammond M, Bunce M, Coovadia HM, Walker BD.

J Virol. 2001 Feb;75(3):1339-47.

15.

Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection.

Goulder PJ, Altfeld MA, Rosenberg ES, Nguyen T, Tang Y, Eldridge RL, Addo MM, He S, Mukherjee JS, Phillips MN, Bunce M, Kalams SA, Sekaly RP, Walker BD, Brander C.

J Exp Med. 2001 Jan 15;193(2):181-94.

16.

Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection.

Altfeld M, Rosenberg ES, Shankarappa R, Mukherjee JS, Hecht FM, Eldridge RL, Addo MM, Poon SH, Phillips MN, Robbins GK, Sax PE, Boswell S, Kahn JO, Brander C, Goulder PJ, Levy JA, Mullins JI, Walker BD.

J Exp Med. 2001 Jan 15;193(2):169-80.

17.

CD8(+) lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: implications for vaccine design and testing.

Allen TM, Mothé BR, Sidney J, Jing P, Dzuris JL, Liebl ME, Vogel TU, O'Connor DH, Wang X, Wussow MC, Thomson JA, Altman JD, Watkins DI, Sette A.

J Virol. 2001 Jan;75(2):738-49.

18.

Early programming of T cell populations responding to bacterial infection.

Mercado R, Vijh S, Allen SE, Kerksiek K, Pilip IM, Pamer EG.

J Immunol. 2000 Dec 15;165(12):6833-9.

19.

Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children.

Goulder PJ, Tang Y, Brander C, Betts MR, Altfeld M, Annamalai K, Trocha A, He S, Rosenberg ES, Ogg G, O'Callaghan CA, Kalams SA, McKinney RE Jr, Mayer K, Koup RA, Pelton SI, Burchett SK, McIntosh K, Walker BD.

J Exp Med. 2000 Dec 18;192(12):1819-32.

20.

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.

Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W, Bilska M, Craiu A, Zheng XX, Krivulka GR, Beaudry K, Lifton MA, Nickerson CE, Trigona WL, Punt K, Freed DC, Guan L, Dubey S, Casimiro D, Simon A, Davies ME, Chastain M, Strom TB, Gelman RS, Montefiori DC, Lewis MG, Emini EA, Shiver JW, Letvin NL.

Science. 2000 Oct 20;290(5491):486-92.

Supplemental Content

Support Center